Home » ATHENAGEN ANNOUNCES PUBLICATION OF RESULTS FROM A PROOF-OF-CONCEPT TRIAL
ATHENAGEN ANNOUNCES PUBLICATION OF RESULTS FROM A PROOF-OF-CONCEPT TRIAL
Athenagen, Inc., a privately held biopharmaceutical company, reported today that its lead compound, GTS-21, a novel, orally active alpha-7 nicotinic acetylcholine (nACh) receptor agonist, demonstrated cognition enhancement activity in a proof-of-concept study in patients with schizophrenia. The study was published in the June issue of the Archives of General Psychiatry,
a peer-reviewed publication of the American Medical Association.
PR
Newswire
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May